The Immune-response and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant - A Prospective, Controlled, Multicenter Cohort Study by the RECOVAC Consortium
Latest Information Update: 12 Aug 2022
At a glance
- Drugs Elasomeran (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Pharmacodynamics
- Acronyms RECOVAC-IR
- 08 Jun 2022 Results (n=113) assessing whether COVID-19 vaccination induces a poor interleukin 21 memory T cell response in kidney transplant recipients, presented at the 2022 American Transplant Congress
- 09 Nov 2021 Primary endpoint of seroconversion rate in hemodialysis as in peritoneal dialysis patients has not been met, according to a results published in the Transplantation.
- 09 Nov 2021 Primary endpoint of seroconversion rate at day 28 after the second vaccination in the kidney transplant recipients has been met, according to a results published in the Transplantation.